Aberrant hypermethylation of RASSF2 in tumors and peripheral blood DNA as a biomarker for malignant progression and poor prognosis of esophageal squamous cell carcinoma

详细信息    查看全文

• 作者：Wei Guo ; Zhiming Dong ; Jianli Cui ; Yanli Guo…
• 关键词：RASSF2 ; Esophageal squamous cell carcinoma ; Expression ; Methylation
• 刊名：Clinical & Experimental Metastasis
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：33
• 期：1
• 页码：73-85
• 全文大小：4,462 KB
• 参考文献：1.Nagaraja V, Eslick GD (2014) Forthcoming prognostic markers for esophageal cancer: a systematic review and meta-analysis. J Gastrointest Oncol 5:67–76PubMedCentral PubMed
  2.Shahbaz Sarwar CM, Luketich JD, Landreneau RJ, Abbas G (2010) Esophageal cancer: an update. Int J Surg 8:417–422CrossRef PubMed
  3.Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220–241CrossRef PubMed
  4.Guohong Z, Min S, Duenmei W, Songnian H, Min L, Jinsong L, Hongbin L, Feng Z, Dongping T, Heling Y, Zhicai L, Shiyong L, Quansheng G, Xiaoyun L, Yuxia G (2010) Genetic heterogeneity of oesophageal cancer in high-incidence areas of southern and northern China. PLoS One 5:e9668PubMedCentral CrossRef PubMed
  5.Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, Schoenberg JB, Mayne ST, Dubrow R, Rotterdam H, West AB, Blaser M, Blot WJ, Gail MH, Fraumeni JF Jr (2003) Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 95:1404–1413CrossRef PubMed
  6.Spandidos DA, Sourvinos G, Tsatsanis C, Zafiropoulos A (2002) Normal ras genes: their onco-suppressor and pro-apoptotic functions. Int J Oncol 21:237–241PubMed
  7.Ponting CP, Benjamin DR (1996) A novel family of Ras-binding domains. Trends Biochem Sci 21:422–425CrossRef PubMed
  8.Donninger H, Vos MD, Clark GJ (2007) The RASSF1A tumor suppressor. J Cell Sci 120:3163–3172CrossRef PubMed
  9.Hesson L, Dallol A, Minna JD, Maher ER, Latif F (2003) NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 22:947–954CrossRef PubMed
  10.Guo W, Dong Z, Chen Z, Yang Z, Wen D, Kuang G, Guo Y, Shan B (2009) Aberrant CpG Island hypermethylation of RASSF1A in gastric cardia adenocarcinoma. Cancer Invest 27:459–465CrossRef PubMed
  11.Guo W, Cui L, Wang C, Guo Y, Shen S, Kuang G, Dong Z (2014) Decreased expression of RASSF1A and up-regulation of RASSF1C is associated with esophageal squamous cell carcinoma. Clin Exp Metastasis 31:521–533CrossRef PubMed
  12.Han L, Dong Z, Wang C, Guo Y, Shen S, Kuang G, Guo W (2014) Decreased expression and aberrant methylation of RASSF5A correlates with malignant progression of gastric cardia adenocarcinoma. Mol Carcinog. doi:10.​1002/​mc.​22245 PubMedCentral
  13.Guo W, Wang C, Guo Y, Shen S, Guo X, Kuang G, Dong Z (2015) RASSF5A, a candidate tumor suppressor, is epigenetically inactivated in esophageal squamous cell carcinoma. Clin Exp Metastasis 32:83–98CrossRef PubMed
  14.Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ (2003) RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem 278:28045–28051CrossRef PubMed
  15.Song H, Oh S, Oh HJ, Lim DS (2010) Role of the tumor suppressor RASSF2 in regulation of MST1 kinase activity. Biochem Biophys Res Commun 391:969–973CrossRef PubMed
  16.Cooper WN, Hesson LB, Matallanas D, Dallol A, von Kriegsheim A, Ward R, Kolch W, Latif F (2009) RASSF2 associates with and stabilizes the proapoptotic kinase MST2. Oncogene 28:2988–2998PubMedCentral CrossRef PubMed
  17.Donninger H, Hesson L, Vos M, Beebe K, Gordon L, Sidransky D, Liu JW, Schlegel T, Payne S, Hartmann A, Latif F, Clark GJ (2010) The Ras effector RASSF2 controls the PAR-4 tumor suppressor. Mol Cell Biol 30:2608–2620PubMedCentral CrossRef PubMed
  18.Huang KH, Huang SF, Chen IH, Liao CT, Wang HM, Hsieh LL (2009) Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma. Clin Cancer Res 15:4174–4180CrossRef PubMed
  19.Zhang Z, Sun D, Van do N, Tang A, Hu L, Huang G (2007) Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Int J Cancer 120:32–38CrossRef PubMed
  20.Kiss NB, Kogner P, Johnsen JI, Martinsson T, Larsson C, Geli J (2012) Quantitative global and gene-specific promoter methylation in relation to biological properties of neuroblastomas. BMC Med Genet 13:83PubMedCentral CrossRef PubMed
  21.Hesson LB, Wilson R, Morton D, Adams C, Walker M, Maher ER, Latif F (2005) CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene 24:3987–3994CrossRef PubMed
  22.Cooper WN, Dickinson RE, Dallol A, Grigorieva EV, Pavlova TV, Hesson LB, Bieche I, Broggini M, Maher ER, Zabarovsky ER, Clark GJ, Latif F (2008) Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer. Oncogene 27:1805–1811PubMedCentral CrossRef PubMed
  23.Wu Y, Zhang X, Lin L, Ma XP, Ma YC, Liu PS (2014) Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer. Asian Pac J Cancer Prev 15:1171–1176CrossRef PubMed
  24.Endoh M, Tamura G, Honda T, Homma N, Terashima M, Nishizuka S, Motoyama T (2005) RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br J Cancer 93:1395–1399PubMedCentral CrossRef PubMed
  25.Maruyama R, Akino K, Toyota M, Suzuki H, Imai T, Ohe-Toyota M, Yamamoto E, Nojima M, Fujikane T, Sasaki Y, Yamashita T, Watanabe Y, Hiratsuka H, Hirata K, Itoh F, Imai K, Shinomura Y, Tokino T (2008) Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer. Carcinogenesis 29:1312–1318PubMedCentral CrossRef PubMed
  26.Schagdarsurengin U, Richter AM, Hornung J, Lange C, Steinmann K, Dammann RH (2010) Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences. Mol Cancer 9:264PubMedCentral CrossRef PubMed
  27.Richter AM, Haag T, Walesch S, Herrmann-Trost P, Marsch WC, Kutzner H, Helmbold P, Dammann RH (2013) Aberrant promoter hypermethylation of RASSF family members in merkel cell carcinoma. Cancers (Basel) 5:1566–1576CrossRef
  28.Park HW, Kang HC, Kim IJ, Jang SG, Kim K, Yoon HJ, Jeong SY, Park JG (2007) Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers. Int J Cancer 120:7–12CrossRef PubMed
  29.Zhao L, Cui Q, Lu Z, Chen J (2012) Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features. Pancreas 41:206–211CrossRef PubMed
  30.Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, Menon U, Stegmaier C, Jacobs IJ, Brenner H (2008) Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One 3:e2656PubMedCentral CrossRef PubMed
  31.Kaaks R, Stattin P, Villar S, Poetsch AR, Dossus L, Nieters A, Riboli E, Palmqvist R, Hallmans G, Plass C, Friesen MD (2009) Insulin-like growth factor-II methylation status in lymphocyte DNA and colon cancer risk in the Northern Sweden Health and Disease cohort. Cancer Res 69:5400–5405CrossRef PubMed
  32.Iwamoto T, Yamamoto N, Taguchi T, Tamaki Y, Noguchi S (2011) BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation. Breast Cancer Res Treat 129:69–77CrossRef PubMed
  33.Wong EM, Southey MC, Fox SB, Brown MA, Dowty JG, Jenkins MA, Giles GG, Hopper JL, Dobrovic A (2011) Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res (Phila) 4:23–33CrossRef
  34.Kondo Y, Shen L, Issa JP (2003) Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol 23:206–215PubMedCentral CrossRef PubMed
  35.Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–408CrossRef PubMed
  36.Sasaki M, Anast J, Bassett W, Kawakami T, Sakuragi N, Dahiya R (2003) Bisulfite conversion-specific and methylation-specific PCR: a sensitive technique for accurate evaluation of CpG methylation. Biochem Biophys Res Commun 309:305–309CrossRef PubMed
  37.Li LC, Dahiya R (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18:1427–1431CrossRef PubMed
  38.Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ, Raval A, Liu TH, Ding W, Mao C, Liu S, Smith LT, Lee S, Rassenti L, Marcucci G, Byrd J, Caligiuri MA, Plass C (2005) Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet 37:265–274CrossRef PubMed
  39.Umemoto M, Yokoyama Y, Sato S, Tsuchida S, Al-Mulla F, Saito Y (2001) Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer. Br J Cancer 85:1032–1036PubMedCentral CrossRef PubMed
  40.Luo D, Ye T, Li TQ, Tang P, Min SD, Zhao GF, Huang H, Chang J, Wang Y, Lv L, Lu ML, Zheng MY (2012) Ectopic expression of RASSF2 and its prognostic role for gastric adenocarcinoma patients. Exp Ther Med 3:391–396PubMedCentral PubMed
  41.Guerrero-Setas D, Pérez-Janices N, Blanco-Fernandez L, Ojer A, Cambra K, Berdasco M, Esteller M, Maria-Ruiz S, Torrea N, Guarch R (2013) RASSF2 hypermethylation is present and related to shorter survival in squamous cervical cancer. Mod Pathol 26:1111–1122CrossRef PubMed
  42.Terry MB, Delgado-Cruzata L, Vin-Raviv N, Wu HC, Santella RM (2011) DNA methylation in white blood cells: association with risk factors in epidemiologic studies. Epigenetics 6:828–837PubMedCentral CrossRef PubMed
  43.Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glöckner S, Piantadosi S, Gabrielson E, Pridham G, Pelosky K, Belinsky SA, Yang SC, Baylin SB, Herman JG (2008) DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358:1118–1128CrossRef PubMed
  44.Gharanei S, Brini AT, Vaiyapuri S, Alholle A, Dallol A, Arrigoni E, Kishida T, Hiruma T, Avigad S, Grimer R, Maher ER, Latif F (2013) RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma. Epigenetics 8:893–898PubMedCentral CrossRef PubMed
  
• 作者单位：Wei Guo (1)
  Zhiming Dong (1)
  Jianli Cui (1)
  Yanli Guo (1)
  Supeng Shen (1)
  Xin Guo (1)
  Gang Kuang (1)
  
  1. Laboratory of Pathology, Hebei Cancer Institute, The Fourth Hospital of Hebei Medical University, Jiankang Road 12, Shijiazhuang, 050011, Hebei, China
  
• 刊物主题：Cancer Research; Biomedicine general; Oncology; Hematology; Surgical Oncology;
• 出版者：Springer Netherlands
• ISSN：1573-7276

文摘

As a tumor suppressor gene, RAS-association domain family 2 (RASSF2) is inactivated by promoter hypermethylation in different tumor cell lines and primary tumors. However, the role of RASSF2 in esophageal squamous cell carcinoma (ESCC) has remained uninvestigated. The aims of this study were to determine the role and methylation status of RASSF2 in esophageal cancer cell lines, ESCC tissues and white blood cells, and to evaluate the potential prognostic role of RASSF2 in ESCC. In the present study, we found frequent silencing of RASSF2 and up-regulation of the gene by 5-Aza-dC treatment in esophageal cancer cell lines. Aberrant methylation of the CpG sites close to the transcription start site induced silencing of RASSF2 expression and in vitro methylation of RASSF2 led to a significant decrease in luciferase activity. The results were further verified in clinical specimens and aberrant methylation of the CpG sites close to the transcription start site of RASSF2 was found in ESCC tumor tissues and peripheral white blood cells. Furthermore, RASSF2 hypermethylation was associated with lower level of RASSF2 expression. ESCC patients in stage III and IV, with negative expression or hypermethylation of the CpG sites close to the transcription start of RASSF2 demonstrated poor patient survival. Taken together, our results suggest that RASSF2 may function as a tumor suppressor gene that is inactivated through hypermethylation of CpG sites close to the transcription start site in ESCC and its expression or methylation may have prognostic implications for ESCC patients. Keywords RASSF2 Esophageal squamous cell carcinoma Expression Methylation